MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/ajh.70443

Медицинская библиотека · American journal of hematology · 2026

Acute Myeloid Leukemia Subtype-Specific Prognostic Value of NGS in the Setting of Intensive Chemotherapy.

Bolarinwa Abiola, Al-Kali Aref, Alkhateeb Hassan B, Mangaonkar Abhishek A, Saliba Antoine N, Torghabeh Mehrdad Hefazi, Matin Aasiya, Elliott Michelle A, Litzow Mark R, Hogan William J, Shah Mithun V, Patnaik Mrinal M, Pardanani Animesh, Foran James M, Badar Talha, Murthy Hermant S, Punwani Nathan, Palmer Jeanne M, Sproat Lisa Z, Chen Dong, Reichard Kaaren K, He Rong, Viswanatha David S, Zepeda-Mendoza Cinthya J, Gangat Naseema, Begna Kebede H, Tefferi Ayalew

СтатьяПеревод в очереди

Аннотация

We examined the prognostic value of routine NGS data in newly diagnosed acute myeloid leukemia (AML) treated with intensive (7 + 3 backbone) induction, specified by AML subtype. A contemporary (2015-2025) series of 545 Mayo Clinic patients (median age 56 years, females 44%) was considered. Median follow-up was 49 months with 341 (63%) allogeneic hematopoietic stem cell transplantations (AHSCT) recorded. AML subtypes included core-binding factor (CBF; N = 72; 13%), primary non-CBF (N = 403; 74%), post-myelodysplastic syndromes (MDS) or post-myelodysplastic/myeloproliferative neoplasms (post-MDS-MDS/MPN; N = 28; 5%), post-MPN (N = 15; 3%), and therapy-related (t-AML; N = 27; 5%). Corresponding complete remission rates, with/without count recovery (CR/CRi), were 89%, 76%, 64%, 27%, and 78% (p < 0.01) and 5-year transplant-censored survival rates 68%, 57%, 21%, 0%, and 55% (p < 0.01). In multivariable analyses, the prognostic value of specific mutations was mostly limited to primary non-CBF AML where adverse karyotype (OR 1.9; p = 0.04) predicted inferior and FLT3-ITD (OR 0.4; p < 0.01) or NPM1 MUT/FLT3 WT (OR 0.1; p < 0.01) superior CR/CRi while KRAS MUT (HR 8.8; p < 0.01), TP53 MUT (HR 5.4; p < 0.01), and TET2 MUT (HR 2.3; p = 0.01) predicted inferior and NPM1 MUT/FLT3 WT (HR 0.3; p = 0.01) superior survival. Prognostication in intensively-treated AML should start with subtype specification and recognition of the limited value of NGS in non-primary AML. Post-MPN AML is particularly associated with dismal outcomes and should be prognostically distinguished from post-MDS-MDS/MPN AML. In primary non-CBF AML, in addition to previously established risk factors, the favorable impact of FLT3-ITD on achieving CR/CRi and the unfavorable impact of KRAS MUT and TET2 MUT on transplant-censored survival were noted and require confirmation from additional studies.

Для цитирования: Bolarinwa Abiola, Al-Kali Aref, Alkhateeb Hassan B, Mangaonkar Abhishek A, Saliba Antoine N, Torghabeh Mehrdad Hefazi, Matin Aasiya, Elliott Michelle A, Litzow Mark R, Hogan William J, Shah Mithun V, Patnaik Mrinal M, Pardanani Animesh, Foran James M, Badar Talha, Murthy Hermant S, Punwani Nathan, Palmer Jeanne M, Sproat Lisa Z, Chen Dong, Reichard Kaaren K, He Rong, Viswanatha David S, Zepeda-Mendoza Cinthya J, Gangat Naseema, Begna Kebede H, Tefferi Ayalew. Acute Myeloid Leukemia Subtype-Specific Prognostic Value of NGS in the Setting of Intensive Chemotherapy.. American journal of hematology. 2026. DOI: 10.1002/ajh.70443.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.